Inhibitor Therapeutics (INTI) Non-Current Deferred Tax Liability (2022 - 2023)
Inhibitor Therapeutics' (INTI) quarterly Non-Current Deferred Tax Liability came in at $55000.0 in Q4 2023, little changed YoY from $55000.0 in Q4 2022, and little changed on a QoQ basis from $55000.0 in Q4 2022.
Inhibitor Therapeutics (INTI) Non-Current Deferred Tax Liability (2022 - 2023) Analysis & Trends
Inhibitor Therapeutics (INTI) has 2 years of Non-Current Deferred Tax Liability data on file, last reported at $55000.0 in Q4 2023.
- Quarterly Non-Current Deferred Tax Liability changed 0.0% year-over-year to $55000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $55000.0 (changed 0.0% YoY) and the FY2023 annual result came in at $55000.0, changed 0.0% from the prior year.
- Non-Current Deferred Tax Liability steadied at $55000.0 in Q4 2023, from $55000.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $55000.0 in Q4 2022 to a low of $55000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 55,000.00 |
| Dec 31, 2023 | 55,000.00 |
| Dec 31, 2022 | 55,000.00 |
| Dec 31, 2022 | 55,000.00 |